Trial Profile
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Ambrisentan (Primary)
- Indications Portal hypertension; Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms ANGEL; Portopulm
- 16 Dec 2020 Status changed from active, no longer recruiting to completed.
- 12 Jan 2020 Results published in the Journal of Heart and Lung Transplantation
- 13 Dec 2019 Planned End Date changed from 1 Oct 2018 to 1 Oct 2020.